health and priority setting in a number of ways. First, as discuse above, it will strengthen the scientific foundation for risk assessments by the delopment ofmore credible exposure/response relationships in people by improving cross-species extrapolation, the development of biologically based dose-response models, and the idetification ofsensitive subpopulations and for "margn of exposure" based estimates of risk Second, it will provide the kind of inrmation necessary for deciding which chemicals should be studied with the limited resources available for toxicological testing. For 
The National Toxicology Program (NTP) was established as a cooperative effort within the Public Health Service of the Department of Health and Human Services (DHHS) to coordinate toxicology research and testing activities within the department; to provide information about potentially toxic chemicals to health regulatory and research agencies, scientific and medical communities, and the public; and to strengthen the science base in toxicology. In its 20 years, the NTP has become the world's leader in designing, conducting, and interpreting various types of assays for toxicity. Through its activities, the NTP provides, directly or indirectly, a large component of the basic scientific data that other federal and state scientific and regulatory agencies, as well as private sector organizations, find useful in responding to issues relevant to the effects of chemical substances on human health and the environment.
In order to meet the responsibilities, NTP strategies and approaches are evolving along a number of fronts. The overall goal of these initiatives is to more efficiently evaluate chemicals for toxic effects using a broad array of test systems and to generate data that strengthen the scientific foundation on which risk assessments are based. The overarching motivation of the program is to use the best science possible in setting priorities, designing and conducting studies, and reporting results in an objective way that best meets the needs of the public and federal and state health and regulatory agencies. We believe that studies which address critical knowledge gaps that create uncertainty in toxicological evaluations offer the best opportunities for preventing environmentally mediated diseases.
Human studies are an increasingly important factor in NTP studies, and opportunities in molecular epidemiology and exposure assessment have produced significant changes in the NTP (1). The human exposure work builds on the National Health and Nutrition Examination Surveys (NHANES), a pioneering federal interagency program in which the Centers for Disease Control and Prevention (CDC) laboratories developed new analytic methods and generated consid- erable human blood and urine data for exposure estimation of the U.S. population (2) . The work also builds on another interagency pilot study lead by the EPA, the National Human Exposure Assessment Survey (NHEXAS), which is designing an exposure surveillance system for the U.S. population. This will obtain periodic and systematic measurements of human exposures to multiple chemicals (3). For example, a major interagency initiative is being developed in exposure assessment, which is frequently the weakest link in risk assessments (4). This initiative, in collaboration with the CDC National Center for Environmental Health (CDC-NCEH), the National Institute for Occupational Safety and Health (NIOSH) , and the EPA, will quantify the body burdens of chemicals released into the environment and workplace and will address a number of public health issues, as discussed later in this commentary. NTP studies aimed at understanding gene/environment interactions will benefit tremendously from the NIEHS's Environmental Genome Project, which will characterize the human variability of hundreds of environmentally relevant genes (5, 6 levels. In addition, trends over time must be determined. We need to know whether body burdens of lead, polychlorinated biphenyls (PCBs), dioxins, volatile organics, and other air and water pollutants are increasing, remaining at the same levels, or decreasing as regulations meant to decrease the levels of these chemicals in the environment are designed and implemented. Workers are frequently exposed to higher levels of many of the 85,000 chemicals in use in the United States than the general public. These chemicals indude benzene, methylene chloride, jet fuel, herbicides, and pesticides. Frequently, the only way to determine actual increase in human body burden is to take blood measurements before and after exposure. Improving the specificity and sensitivity of the chemical tests now available for this purpose will allow small blood samples to be used to generate data of high quality on the relationship between workplace exposure circumstances and worker exposure. This information is critical in priority setting. Chemicals found in a high proportion of the population or in high amounts in certain segments of the population would be given a high priority for toxicological and epidemiological studies. Furthermore, the design of studies will benefit from knowledge ofchemical levels in the general population being used to select low doses for NTP studies that will be relevant to the real world. (Fig. 2) .
The NIEHS Environmental Genome Project will be a broad, multicenter effort to identify systematically in the U.S. population the alleles of 200 or more environmental disease susceptibility genes (5). A central database of the polymorphisms will be made available. This database will in turn support both functional studies of alleles and population-based studies of disease risk. Such population-based epidemiologic studies are central to the identification of both the allelic differences and the environmental exposures that cause disease, and represent an integral application of the Environmental Genome Project.
Working with genetically susceptible subgroups will allow us to identify more precisely the environmental agents that cause disease and the true risks of exposure. Results from the Environmental Genome Project will lead to public health programs 1) for protecting susceptible populations, 2) for targeted screening of groups at higher risk of disease, and 3) for more definitive epidemiology studies including evaluation in sensitive populations, provided that credible exposure indices are available.
After all, if we wish to improve our understanding of exposure/response relationships in sensitive subpopulations, we must have credible exposure data.
Risk Assessment
The recent flurry of activity and intense controversy associated with health risk assessment and its use in regulatory decisions is generated by a number of forces, induding concerns of industry that costs of complying with environmental regulations are excessive, concerns of environmentalists that risk assessment practices and policies do not adequately protect human and environmental health, the public's lack of confidence in regulatory decision making, and increasing awareness that the scientific foundation for many risk assessments is weak (17).
Resolution of the controversy, development of effective prevention strategies, and rational priority setting can only be achieved by strengthening the database used to make regulatory decisions. A recent estimate of federal expenditures for health risk assessment-related research is $600 million/year (18); however, this figure is probably greater than the actual dollars spent. Although this seems to be a huge sum, it is negligible in comparison to the costs of the consequences of regulatory decisions. The NIEHS and the CDC currently are collaborating on a pilot project for quantifying approximately 70 chemicals that are considered to be endocrine disruptors in either human blood and urine (4). This collaboration will strengthen the science base for risk assessments in a number of ways. For Broad-based knowledge on the quantities of different chemicals in people's bodies will facilitate the evolution of mixture research to take advantage of the tools of molecular toxicology. For example, a first step in using reallife mixtures could be to test them in highthroughput molecular screens to determine if mixtures are causing changes in gene expression or other early critical events in toxicity. It will also be possible, using such approaches, to evaluate whether the mixture is modifying the toxicity of individual components of that mixture (i.e., increased DNA damage from polycyclic aromatic hydrocarbons). Results from the molecular screens would be used to set priorities for further research including more time-consuming animal toxicology and/or molecular epidemiologic studies. This approach ensures that valuable resources are not wasted on the study of low priority mixtures.
In summary, the exposure assessment initiative is needed to address public health issues and to enhance the NTP's ability to meet its public health goals. It :... Environmental Health Perspectives * Volume 106, Number 10, October 1998
